{"id":"NCT00877006","sponsor":"Teva Branded Pharmaceutical Products R&D, Inc.","briefTitle":"Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With R-CVP or R-CHOP in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL) - Referred to as the BRIGHT Study","officialTitle":"An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab (BR) Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkin's Lymphoma (NHL) or Mantle Cell Lymphoma (MCL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04-30","primaryCompletion":"2012-03-31","completion":"2012-03-31","firstPosted":"2009-04-07","resultsPosted":"2014-04-28","lastUpdate":"2018-02-05"},"enrollment":447,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Non-Hodgkin's Lymphoma","Mantle Cell Lymphoma"],"interventions":[{"type":"DRUG","name":"bendamustine","otherNames":["Treakisym","Ribomustin","Levact","Treanda","SDX-105"]},{"type":"DRUG","name":"rituximab","otherNames":["Rituxan","MabThera","Zytux"]},{"type":"DRUG","name":"vincristine","otherNames":["Oncovin"]},{"type":"DRUG","name":"prednisone","otherNames":[]},{"type":"DRUG","name":"cyclophosphamide","otherNames":["Endoxan","Cytoxan","Neosar","Procytox","Revimmune"]},{"type":"DRUG","name":"doxorubicin","otherNames":["Adriamycin"]}],"arms":[{"label":"Bendamustine and Rituximab (BR)","type":"EXPERIMENTAL"},{"label":"R-CHOP/R-CVP","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of the study is to compare the complete response (CR) rate of bendamustine and rituximab (BR) with that of standard treatment regimens of either rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) or rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with advanced, indolent non-Hodgkin's lymphoma (NHL) or mantle cell lymphoma (MCL).","primaryOutcome":{"measure":"Percentage of Participants With Complete Response (CR) at End of Treatment Period","timeFrame":"6 to 8 21 or 28-day cycles (18-32 weeks)","effectByArm":[{"arm":"Bendamustine and Rituximab (BR)","deltaMin":31,"sd":null},{"arm":"R-CHOP/R-CVP","deltaMin":25,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":14,"exclusionCount":15},"locations":{"siteCount":128,"countries":["United States","Australia","Brazil","Canada","Mexico","New Zealand","Peru"]},"refs":{"pmids":["24591201","30811293","26875824"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":60,"n":221},"commonTop":["Nausea","Fatigue","Neutropenia","Constipation","Infusion related reaction"]}}